Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
To access this article, please choose from the options below
Conflicts of Interest The authors disclose the following: T. Poynard, M. Colombo, S. Flamm, T. Berg E. Schiff, E. J. Heathcote, A. Craxi, M. Silva, and W. Schmidt are members of the speakers bureau for Schering–Plough; A. Craxi, E. J. Heathcote, and W. Schmidt are members of the speakers bureau for Roche; T. Poynard, M. Colombo, E. Schiff, M. Diago, S. Flamm, T. Berg, A. Craxi, M. Silva, E. J. Heathcote, and F. Gonçales receive research support from Schering–Plough; A. Craxi receives research support from Roche; S. Flamm receives research support from Valeant and serves on the speakers bureau for Novartis; M. Colombo, E. Schiff, A. Craxi, J. Bruix, and E. J. Heathcote are consultants for Schering–Plough; A. Craxi is a consultant for Roche; L. Griffel, M. Burroughs, C. Brass, J. K. Albrecht, and P. Mukhopadhyay are employees of Schering–Plough Research Institute and stock holders of Schering–Plough; R. Moreno-Otero, F. Carrilho, R. Terg, P. Bedossa, and T. McGarrity have nothing to disclose. Study participants were told of investigators' conflicts of interests.
Funding Schering–Plough Research Institute fully supported the study. Role of study sponsor: Schering–Plough Research Institute played a major role in the study design. They collected, analyzed, and performed the initial interpretation of all data. All the authors provided input and agreed to the final interpretation. The decision to submit the report was made by Schering–Plough Research Institute in conjunction with the publication committee.
The complete list of the EPIC Study Group membership appears in the online Appendix.
PII: S0016-5085(09)00102-4
doi:10.1053/j.gastro.2009.01.039
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.

